A
Andrew Jack
Researcher at Leeds Teaching Hospitals NHS Trust
Publications - 175
Citations - 13772
Andrew Jack is an academic researcher from Leeds Teaching Hospitals NHS Trust. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Follicular lymphoma. The author has an hindex of 53, co-authored 175 publications receiving 12641 citations. Previous affiliations of Andrew Jack include University of Leeds & European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Robert Marcus,Kevin Imrie,Andrew R. Belch,David Cunningham,Eduardo Flores,John Catalano,Philippe Solal-Celigny,Fritz Offner,Jan Walewski,João Raposo,Andrew Jack,Paul Smith +11 more
TL;DR: The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.
Journal ArticleDOI
Isolation and Characterization of Bone Marrow Multipotential Mesenchymal Progenitor Cells
Elena Jones,Sally E. Kinsey,Anne English,Richard A. Jones,Liz Straszynski,David Meredith,Alex F. Markham,Andrew Jack,Paul Emery,Dennis McGonagle +9 more
TL;DR: This study shows the distinct phenotype, morphology, and method of isolation of BM MPCs, which may have implications for defining the physiologic roles of MPCs in arthritis, bone diseases, and joint regeneration.
Journal ArticleDOI
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hervé Tilly,M. Gomes da Silva,Umberto Vitolo,Andrew Jack,Michel Meignan,Armando López-Guillermo,Jan Walewski,Marc André,Peter Johnson,Michael Pfreundschuh,Marco Ladetto +10 more
TL;DR: This work presents the results of a double-blind, placebo-controlled study conducted at the University of Southampton over a two-week period in June and July of last year that demonstrated clear trends in prognosis for breast cancer in smokers and women with a history of smoking.
Journal ArticleDOI
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers,Richard Klasa,Robert E. Marcus,Max Wolf,Eva Kimby,Randy D. Gascoyne,Andrew Jack,Mars B. van ’t Veer,Andrej Vranovsky,Harald Holte,Martine Van Glabbeke,I. Teodorovic,Cynthia Rozewicz,Anton Hagenbeek +13 more
TL;DR: This is the first trial showing that in relapsed/resistant FL rituximab maintenance considerably improves PFS not only after CHOP but also after R-CHOP induction.
Journal ArticleDOI
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.
TL;DR: In this article, the authors reported the incidence of haematological malignancy by sub-type. But they did not specify the sub-types of the malignancies.